GH and Kidney
Risk of Mortality in Patients with End-Stage Renal Disease: The Role of Malnutrition and Possible Therapeutic ImplicationsZeier M.
Department of Medicine, Division of Nephrology, University of Heidelberg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The mortality rate of dialysis patients is still considerably high. Beside the traditional risk factors, specific uremia-related risk factors are identified. Among them, hypoalbuminemia and malnutrition have a strong association to mortality in chronic dialysis patients. Various studies document a strong relation between reduced calorie and protein uptake and mortality in uremic patients. Several factors responsible for malnutrition in dialysis patients have been identified. These factors may be dialysis-associated, due to intercurrent illnesses or are associated with uremic complications (e.g. hyperparathyroidism, anemia, acidosis, etc.). Malnutrition is treatable and can be avoided by several means. Beside the increase in the dose of dialysis and adequate protein and calorie intake, intradialytic nutrition is an additional choice. The combination with specific drugs (e.g. growth hormone) may potentiate the success of the modified treatment modalities, particularly in patients who need nutritional support during an intercurrent illness. Further studies are required to measure the impact of for example growth hormone supplementation on mortality rate and quality of life in malnourished patients on chronic dialysis.
© 2002 S. Karger AG, Basel
Foley RN, Parfrey PS, Sarnack MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998;32(suppl 3):S112–S119.
US Renal Data System: Annual Data Report. National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, Md, 1998.
Locatelli F, Marcelli D, Ferrucio C, D’Amico M, DelVecchio L, Limido A, Malberti F, Spotti D for the Registro Lombardo Dialisi e Trapianto: Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol Dial Transplant 2000;15(suppl 5):69–80.
- Kavanagh D, Morris ST, Northridge DB, Rodger RS, Jardine AG: Electrocardiogram and outcome following renal transplantation. Nephron 1999;81:109–110.
- Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK: Long-term survival in renal transplant recipients with graft function. Kidney Int 2000;57:307–313.
Parfrey PS: Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000;15(suppl 5):58–68.
Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazurus JM: The urea reduction ratio and serum albumin concentrations as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329:1061–1066.
- Kaminski MV Jr, Lowrie EG, Rosenblatt SG, Haase T: Malnutrition is lethal, diagnosable and treatable in ESRD patients. Transplant Proc 1991;23:1810–1815.
- Blagg CR: Importance of nutrition in dialysis patients. Am J Kidney Dis 1991;17:458–461.
- Allman MA, Allen BJ, Stewart PM, Blagojevic N, Tiller DJ, Gaskin KJ, Truswell AS: Body protein of patients undergoing haemodialysis. Eur J Clin Nutr 1990;44:123–131.
Wolfson M, Strong CJ, Minturn RD, Gray DK, Kopple JD: Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 1984;37:547–555.
- Degoulet P, Legrain M, Reach I, Aimes F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated with hemodialysis. Nephron 1982;31:103–110.
- Kopple JD: McCollum Award Lecture, 1996:Protein-enery malnutrition in maintenance hemodialysis patients. Am J Clin Nutr 1997;65:1544–1557.
Mattern MD, Hak LJ, Lamanna RW, Teasley KM, Laffell MS: Malnutrition, altered immune function and the risk of infection in maintenance hemodialysis patients. Am J Kidney Dis 1992;1:206–218.
- Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458–482.
- Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125–137.
Parker TF, Laird NM, Lowrie EG: Comparison of the study groups in the National Cooperative Dialysis Study and a description of morbidity, mortality and patient withdrawal. Kidney Int 1983;23:199–203.
Acchiardo SR, Moore LW, Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int 1983;24(suppl 16):199–203.
- Oksa H, Ahonen K, Pasternak A, Marnela KM: Malnutrition in hemodialysis patients. Scand J Urol Nephrol 1991;25:157–161.
Levin NW, Held P, Port FK, Agodoa L: Comorbid factors are not the reason for hypoalbuminaemia in incident hemodialysis patients. J Am Soc Nephrol 1992;3:376.
- Blumenkrantz MJ, Kopple JD, Gutman RA, Chan YK, Barbour GL, Roberts C, Shen FH, Gandhi VC, Tucker CT, Curtis FK, Coburn JW: Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr 1980;33:1567–1585.
Bischel M: Albumin turnover in chronically hemodialyzed patients. Trans Am Soc Intern Organs 1969;15:298–304.
- Ooi BS, Dacrocy AF, Pollak VE: Serum transferrin levels in chronic renal failure. Nephron 1972;9:200–204.
- Jakob V, Le Carpentier JE, Salzano S, Naylor V, Wild G, Brown CB, el-Nahas AM: IGF-1, a marker of undernutrition in hemodialysis patients. Am J Clin Nutr 1990;52:39–44.
- Borah MF, Schoenfeld PY, Gotch FA: Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978;14:491–500.
Depner TA: Standards for dialysis adequacy. Semin Dial 1991;4:245–252.
Modification of Diet in Renal Disease (MDRD) Study Group, prepared by Kopple J, Berg R, Houser H, Steinman T, Teschan P: Nutritional status of patients with different levels of chronic renal insufficiency. Kidney Int 1989;36(suppl 27):S184–S194.
- El-Lakany S, Eagon PK, Gavaler JS, Schade RR, Whiteside T, Van Thiel DH: Gastrointestinal function, morphology and immune status in uremia. Nutrition 1990;6:461–468.
- Maroni B, Steinman TI, Mitch NE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58–61.
Charra B, Hurot JM, Chazot C, VoVan C, Jean G, Terrat JC, Vanel T, Ruffet M, Laurent G: Comparison of survival data. Kidney Int 2000;58:901–902.
Lindsay R, Spanner E, Allison M: Which comes first, Kt/V or PCR – chicken or egg? Kidney Int 1992;42(suppl 38):S32–S37.
- Hakim RM, Depner TA, Parker TF: Adequacy of hemodialysis. Am J Kidney Dis 1992;20:107–123.
- Kopple JD: Therapeutic approaches to malnutrition in chronic dialysis patients: The different modalities of nutritional support. Am J Kidney Dis 1999;33:180–185.
- Kopple JD, Bernard D, Swartz R, Messana J, Bergstrom J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink LD, Martis L, Algrim-Boyle C, Serkes KD, Vonesh E, Jones MR: Treatment of malnourished CAPD patients with amino acid based dialysate. Kidney Int 1995;47:1148–1157.
- Chazot C, Shahmir E, Matias B, Laidlaw S, Kopple JD: Dialytic nutrition: Provision of amino acids in dialysate during hemodialysis. Kidney Int 1997;52:1663–1670.
- Snyder S, Bergen C, Sigler MH, Teehan BP: Intradialytic parenteral nutrition in chronic hemodialysis patients. ASAIO Trans 1991;37:M373–M375.
- Madigan KM, Olshan A, Yingling DJ: Effectiveness of intradialytic parenteral nutrition in diabetic patients with end-stage renal disease. J Am Diet Assoc 1990;90:861–863.
- Canaud B, Bouloux C, Rivory JP, Taib J, Garred LJ, Florence P, Mion C: Erythropoietin-induced changes in protein nutrition: Quantitative assessment by urea kinetic modelling analysis. Blood Purif 1990;8:301–308.
- Barany P, Petterson E, Ahlberg M, Hultman E, Bergstrom J: Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1991;35:270–279.
- Schulman G, Wingard RL, Hutchinson RL: The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis 1993;21:527–534.
- Ziegler TR, Lazarus JM, Young LS, Hakim R, Wilmore DW: Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991;2:1130–1135.
- Kopple JD: The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure. Miner Electrolyte Metab 1992;18:269–275.
- Garibotto G, Barreca A, Russo R, Sofia A, Arathi P, Cesarone A, Malaspina M, Fiorini F, Minuto F, Tizianello A: Effects of recombinant growth hormone in muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997;99:97–105.
- Johannsson G, Bengtsson BA, Ahlmen J: Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999;33:709–717.
- Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pederson FB: Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000;53:99–107.
- Jensen PB, Ekelund B, Nielsen FT, Baumbach L, Pedersen FB, Oxhoj H: Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin Nephrol 2000;53:25–32.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.